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Background 
Malaria in pregnant women can cause severe maternal 
anaemia and low birthweight babies. Drugs to be used 
must not be harmful for mothers or babies. There is 
widespread drug resistance of P falciparum.   
Inclusion criteria 
Studies:  
Randomized and quasi-randomized controlled trials.  
Participants: 
Pregnant women with uncomplicated falciparum 
malaria confirmed by a blood slide. 
Intervention: 
Antimalarial drug combinations. 
Outcomes: 
In the mother: treatment failure. 
In the babies: low birthweight, congenital abnormalities, 
stillbirths, abortions, pre-term delivery. 
Results 
Ten trials involving 1805 women were included 
(eight randomized and two quasi-randomized); three 
had adequate allocation concealment. Five trials 
were conducted in South-East Asia and five in 
different African countries: 
• In a refugee camp on the Thailand-Myanmar border: 
◊ The following gave fewer treatment failures on 
day 63 compared with quinine: artesunate plus 
avatone-proguanil (relative risk 0.24, 95% 
confidence interval 0.10 to 0.57, 80 participants, 
1 trial), and artesunate plus mefloquine (RR 0.09, 
95% confidence interval 0.02 to 0.38; 106 
participants, 1 trial). 
◊ Artesunate gave fewer treatment failures at 48 
hours than quinine plus clindamycin (RR 0.21, 
95% CI 0.12 to 0.38; 129 participants, 1 trial), 
but by day 42 all women were cured. 
• In Southern Africa: 
◊ Compared with sulphadoxine-pyrimethamine 
alone, treatment failure at day 40 was reduced by 
adding artesunate (RR 0.21, 95% CI 0.07 to 0.70; 
94 participants, 1 trial) or azithromycin (RR 0.29, 
95% CI 0.10 to 0.80; 94 participants, 1 trial). 
• In West Africa: 
◊ Compared with chloroquine, there were fewer 
treatment failures at day 28 with amodiaquine 
(RR 0.25, 95% CI 0.15 to 0.42; 420 participants, 
1 trial), sulphadoxine-pyrimethamine (RR 0.46, 
95% CI 0.33 to 0.64; 538 participants, 2 trials) or 
amodiaquine plus sulfadoxine-pyrimethamine 
(RR 0.02, 95% CI 0.03 to 0.19; 418 participants). 
• There were no significant differences between any of 
the drug combinations in adverse outcomes for the 
babies. 
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Which drugs should be used against uncomplicated falciparum malaria 
in pregnant women?  
Some drug combinations seem effective against malaria in pregnancy, 
but there is not much information about drug safety.  
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Authors’ conclusions 
Implications for practice:  
In South-East Asia, artesunate plus mefloquine and artesunate plus atovaquone-proguanil may be better than 
quinine. 
In Southern Africa, combinations of  artesunate or azithromycin with sulfadoxine-pyrimethamine may be better 
than sulfadoxine-pyrimethamine alone. 
In West Africa, amodiaquine or  amodiaquine plus sulfadoxine-pyrimethamine may be better than chloroquine. 
Implications for research: 
Further randomized controlled trials evaluating different drug treatments for malaria in pregnancy are needed. 
These trials should assess both effectiveness and safety in the mother and baby. 
Artesunate plus mefloquine vs quinine: treatment failure at day 63 
 
 
